Avita Medical Aims for Q4 2025 Cash Flow Breakeven as Revenue Grows
Avita Medical Inc., a regenerative medicine company, has raised its 2025 revenue guidance to $86 million–$89 million. The company expects to reach cash flow breakeven in Q4 2025, supported by declining cash use, stable o